Entrada Therapeutics, Inc.
TRDA
Positions held
Your positionsTRDA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $215.32M | Enterprise value | $24.93M | Trailing P/E | — | Forward P/E | -1.84 |
| PEG | — | Price / book | 0.85 | Beta | -0.24 | Dividend yield | 0.00% |
| Revenue growth | -53.9% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -50.1% |
| Profit margin | 0.0% | ROE | -54.1% | ROA | -29.2% | Debt / equity | 0.21 |
| Current ratio | 10.89 | Free cash flow | -$77.67M | Analyst recommendation | none | Mean target | $19.00 |
| 52w high | $16.45 | 52w low | $5.15 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.9M | $0.9M | $1.3M | $1.6M | $1.9M |
| Op margin | -5007.0% | -4834.6% | -3249.3% | -2915.2% | -2402.5% |
| Net income | -$42.8M | -$39.7M | -$39.2M | -$44.1M | -$43.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$45.0M | -$42.3M | -$42.2M | -$47.1M | -$46.8M |
- Revenue +3% vs prior quarter ($0.9M vs $0.9M).
- Operating margin compressed to -5007%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $25.4M | $211M | $129M | $0.0M | — |
| Op margin | -621.1% | 22.3% | -2.5% | — | — |
| Net income | -$144M | $65.6M | -$6.7M | -$94.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$158M | $47.0M | -$3.2M | -$97.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-10 · Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
2026-09-02 · Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05 · Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
2026-08-05 · Entrada Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-03 · Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing
2026-07-30 · Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns